Cargando…
Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis
BACKGROUND: The majority of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia gravis (GMG), usually within 2 years of disease onset. The aim of this meta-analysis was to evaluate the effect of early prednisolone and other immunosuppressants therapy on the generalization...
Autores principales: | Li, Mingxia, Ge, Fangfang, Guo, Rongjing, Ruan, Zhe, Gao, Yanwu, niu, Chunxiao, Lin, Hong, Zhao, Zhengwei, Zhou, Yongan, Li, Zhuyi, Chang, Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842340/ https://www.ncbi.nlm.nih.gov/pubmed/35173803 http://dx.doi.org/10.1177/1756286419876521 |
Ejemplares similares
-
Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta‐analysis
por: Wang, Liang, et al.
Publicado: (2019) -
Melatonin exerts immunoregulatory effects by balancing peripheral effector and regulatory T helper cells in myasthenia gravis
por: Chang, Ting, et al.
Publicado: (2020) -
Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis
por: Ruan, Zhe, et al.
Publicado: (2022) -
Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China
por: Ding, Jiaqi, et al.
Publicado: (2020) -
PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis
por: Xiong, Xunbo, et al.
Publicado: (2015)